全國服務咨詢熱線：
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 1801747-11-4 |
|---|---|---|---|
| 分子式 | C16H20Cl3N5 | 純度 | >98 % |
| 分子量 | 388.72 | 貨號 | abs810051 |
| 規格 | 5mg;25mg;100mg | 供貨周期 | 現貨 |
| 主要用途 | - | 應用領域 | 化工,生物產業,綜合 |
| 產品描述 | |
| 描述 | SHP099 exhibits dose-dependent pathway inhibition and antitumor activity in xenograft models. SHP-099 stabilizes SHP2 in an auto-inhibited conformation, concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models. SHP099’s activity provides evidence that pharmacological inhibition of SHP2 is a viable strategy to target RTK-driven cancers and presents a new chemical tool for further interrogation of the multifaceted cellular functions of SHP2 in development, tumorigenesis, RTK-driven drug resistance and immune-checkpoint modulation.SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest. |
| 純度 | >98 % |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | SHP-099鹽酸鹽；SHP099 HCl |
| 外觀 | 粉劑 |
| 可溶性/溶解性 | Water : 7.69 mg/mL(19.78 mM), Need ultrasonic and warming DMSO : 4.1 mg/mL (10.55 mM; Need ultrasonic and warming) |
| 生物活性 | |
| 靶點 | SHP2 |
| In vitro(體外研究) | The X-ray co-crystal for SHP099 with SHP2 reveals a new interaction with the basic amine and the Phe113 backbone carbonyl. SHP099 shows inhibition of cell proliferation (KYSE-520 model) with an IC50 of 1.4 μM. SHP099 shows high solubility and high permeability with no apparent efflux in Caco-2 cells. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells. |
| In vivo(體內研究) | After a single doses of 30 and 100 mg/kg (red and blue lines, respectively), dose-dependent exposure and modulation of the pharmacodynamic marker p-ERK is observed in the xenografts. A daily oral dose of 10 or 30 mg/kg yield 19% and 61% tumor growth inhibition, respectively. Tumor stasis is achieved at 100 mg/kg. |
| 分子結構圖 | |
 | |
| 溫馨提示：本產品僅作科研實驗使用，不支持臨床等研究 |
產品咨詢
電話
微信掃一掃
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：wulan@absin.cn
傳真：